# Macrophage Polarization in CLL â€” TF Activity Signature Pipeline


**Affiliation:** INSERM U1037 â€“ Centre de Recherches en CancÃ©rologie de Toulouse (CRCT)  
**Period:** 2020â€“2023  
**Publication:** [Cancers, 2020](https://www.mdpi.com/2072-6694/12/12/3664)  

---
This repository contains the code and documentation developed during the INSERM/CRCT project on **macrophage polarization** in the context of **Chronic Lymphocytic Leukemia (CLL)**.
Macrophages in CLLâ€™s tumor microenvironment can differentiate into **Nurse-Like Cells (NLCs)**, a tumor-supportive phenotype that promotes leukemic cell survival and immune escape.

This project implements a **modular Python pipeline** to extract and analyze transcription factor (TF) activity signatures (M1, M2, NLC) using **DoRothEA / VIPER** and explore their relevance to macrophage plasticity.

---

## Biological Background

Macrophage phenotypes are shaped by cytokines, transcription factors, and environmental cues:

* **M1 macrophages** â†’ pro-inflammatory, anti-tumoral
* **M2 macrophages** â†’ anti-inflammatory, tissue repair, immunoregulatory
* **NLCs (Nurse-Like Cells)** â†’ CLL-associated macrophages with tumor-supportive functions

NLCs arise when CLL cells reprogram macrophages through:

* direct contact (e.g., CD40L, integrins)
* cytokines (IL-10, BAFF, APRIL)
* altered NF-ÎºB / STAT3 / PI3K signaling

Understanding the **regulatory programs** driving these phenotypes requires both transcriptomic analysis and integrative modelling.

---

## Project Objectives

* Infer TF activities for macrophages exposed to CLL/TME cues.
* Classify TFs into dominant polarization programs (**M1**, **M2**, **NLC**).
* Export signature sets describing regulatory identities of each phenotype.

---

## Methods Overview

### **1. Input Data**

Scaled TF activity matrix generated from Dorothea / DoRothEA.

### **2. TF Signature Extraction**

For each TF, compute contributions to M1, M2, and NLC phenotypes, then assign the dominant signature.

### **3. Output**

* Signature files for **M1**, **M2**, **NLC**
* Summary table
* Python objects for downstream analysis
* Optional visualization via `notebook_pipeline.ipynb`

---

## ðŸ—‚ Repository Structure

```
02_BooleanModel/
â”‚
â”œâ”€â”€ README.md                  # (This file)
â”œâ”€â”€ notebook_pipeline.ipynb    # Exploratory usage & visualization
â”œâ”€â”€ run_pipeline.py            # CLI entry point
â”‚
â”œâ”€â”€ data/
â”‚   â”œâ”€â”€ input/                 # Dorothea TF activity tables
â”‚   â””â”€â”€ output/                # Generated M1/M2/NLC signatures
â”‚
â””â”€â”€ src/
    â”œâ”€â”€ __init__.py
    â”œâ”€â”€ io.py                  # File loading / writing utilities
    â”œâ”€â”€ pipeline.py            # Core logic for TF signature extraction
    â”œâ”€â”€ signatures.py          # Scoring & signature attribution
    â””â”€â”€ utils.py               # Timer & miscellaneous helpers
```

---

## Pipeline Diagram

```mermaid
flowchart TD

    A[Load Dorothea TF activity .tsv] --> B[Parse TF rows & normalize data]
    B --> C[Compute M1 / M2 / NLC scores]
    C --> D[Assign dominant phenotype for each TF]
    D --> E[Write signature files to data/output]
    C --> F[Return signature sets<br>for M1 / M2 / NLC]
    E --> G[Print summary]
    F --> G
```

---

## Usage

### Full pipeline

```bash
python run_pipeline.py
```

### Specific step only

```bash
python run_pipeline.py --step signatures
```

Results appear in:

```
data/output/
```

---

## Interpretation of Outputs

The pipeline yields:

* **NLC-associated TFs**
  â†’ often linked to STAT3, PI3K/AKT, NF-ÎºB, immunosuppression, CLL-support functions.

* **M1-associated TFs**
  â†’ STAT1, IRF1/7, NF-ÎºB-driven inflammatory axis.

* **M2-associated TFs**
  â†’ C/EBPÎ², PPARÎ³, KLF4, homeostatic anti-inflammatory regulators.

Comparing these signatures helps identify transcriptional routes by which CLL cells reprogram macrophages.

---

## Reference
Marku M., *Verstraete N.*, et al. *Insights on TAM Formation from a Boolean Model of Macrophage Polarization Based on In Vitro Studies.*  
*Cancers*, 2020. [DOI:10.3390/cancers12123664](https://www.mdpi.com/2072-6694/12/12/3664)























